Sample 20

Evaluation Instructions

Important: Models were tasked with extracting evidence from documents. Some outputs may be low quality and should be scored accordingly.

Your task: Compare the model-generated prediction (right panel) against the ground truth criteria (left panel).

Clean view: Shows formatted, readable text for easy comparison
Diff view: Highlights differences between ground truth and prediction
Raw view: Shows original unformatted text as it appears in the dataset

Evaluation scale (0-4):

0 = No match: Prediction is unrelated or contradicts the target criteria
1 = Poor match: Minimal overlap with ground truth, major errors or omissions
2 = Partial match: Some key elements captured, but notable gaps or inaccuracies
3 = Good match: Most elements correct, minor differences or formatting issues
4 = Excellent match: Essentially identical content, fully correct capture

Consider both content accuracy and completeness. Some predictions may be technically "correct" but incomplete or out of order.

Ground Truth

INCLUSION CRITERIA

  1. Adult male subject aged 18 to 65 years inclusiveBMI > 30 kg/m2 and < 50 kg/m2
  2. Serum total testosterone concentration below the normal rangeLH levels below the upper limit of normal
  3. Oestradiol levels within or above the normal range of approved assayAt least two symptoms of androgen deficiency present for at least 2 months prior to the first Screening Visit, with at least one of these being a sexual dysfunction

EXCLUSION CRITERIA

  1. Evidence of clinically significant endocrinopathy at screening that may interfere with the study assessments
  2. Other types of hypogonadotropic hypogonadism or primary hypogonadism
  3. Any other pituitary or hypothalamic disease

Prediction

Modified Eligibility Criteria for Clinical Trial Version 10

INCLUSION CRITERIA

1. Age: Adult male, aged 18 to 65 years inclusive.
2. BMI: BMI > 30 kg/m2
3. HbA1c: HbA1c ≤ 10.5% at Screening.
4. Type 2 Diabetes:
5. HbA1c ≤ 10.5% at Screening.
6. Anti-diabetic medication regimen (excluding insulin) has been stable for ≥ 8 weeks before the first Screening visit.
7. Other

EXCLUSION CRITERIA

1. History of monoclonal antibodies, insulin, or other medications known to affect sex hormone production within the 4 weeks prior to the first Screening Visit.
2. Weight loss or weight gain (gain or loss > 5% body weight) OR weight reduction surgery or procedure within the 3 months prior to first Screening Visit.
3. Participation in any clinical trial using clinical investigational product intervention within 3 months before first Screening Visit or 5 half-lives of investigational product administration, whichever is longer.
4. Medical history of Long QT syndrome.
5. History of thromboembolic disease.
6. Grade ≥3 lower extremity oedema.
7. Use of cardiac pacemaker or other medical electronic devices that can be affected by bioimpedance assessment.
8. Medical diagnosis of any of the following cardiovascular conditions within the 6 months prior to first Screening Visit:
9. Myocardial infarction or unstable angina.
10. Coronary artery bypass surgery, balloon angioplasty, percutaneous coronary intervention or carotid revascularisation procedure.
11. Uncontrolled hypertension within the 3 months prior to first Screening Visit.
12. Significant cardiac arrhythmia (as determined by the investigator).
13. Endovascular procedure or surgical intervention for peripheral vascular disease within the 3 months prior to first Screening Visit.
14. Advanced ischemic heart disease.
15. Note:** The specific inclusion and

EXCLUSION CRITERIA

1. may vary depending on the version of the protocol.